#230 Less puffing, more breathing? Intermittent inhaled steroids for asthma
CLINICAL QUESTION
In patients with mild persistent asthma, is intermittent use of inhaled corticosteroids (ICS) as effective as daily use?
BOTTOM LINE
In patients with mild persistent asthma, intermittent use of ICS or ICS/LABA is similar to daily ICS in preventing exacerbations but is associated with ~5 fewer weeks per year of well-controlled asthma. Overall adverse events are similar.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Focusing on two large (~4000 patients each), industry managed, randomized, double-blind, placebo-controlled trials (RCTs) in mild persistent asthma (controlled on low-dose daily ICS or uncontrolled with Short-Acting Beta-Agonist alone).1,2 Mean age ~40; ~20% had severe exacerbation in preceding year. Included patients randomized to budesonide/formoterol PRN or budesonide 200mcg BID + terbutaline PRN after a 2-4-week run-in of terbutaline only. Outcomes at 1 year (study results combined when similar outcomes reported):
- Patients with ≥ exacerbation:
- Severe exacerbations (oral steroids, hospitalization or emergency department visit with systemic corticosteroids):1,2
- Budesonide/formoterol PRN 7.4%, daily ICS 7.8%: not statistically different.
- Moderate to severe exacerbations:1
- Budesonide/formoterol PRN 10.3%, daily ICS 11.2%: not statistically different.
- Severe exacerbations (oral steroids, hospitalization or emergency department visit with systemic corticosteroids):1,2
- Symptoms:
- Asthma Control Questionnaire-5 (ACQ-5): nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheeze:
- Proportion with improvement of ≥ 0.5 points (minimally clinical important difference):1,2
- Budesonide/formoterol PRN 41%, daily ICS 46%, Number needed to harm (NNH)=20.
- Number of weeks with well controlled asthma:
- Budesonide/formoterol PRN 18 weeks versus 23 weeks.1
- Asthma Quality of Life Questionnaire: no clinically meaningful difference.1,2
- Proportion with improvement of ≥ 0.5 points (minimally clinical important difference):1,2
- Adverse events: similar.1,2
- Total ICS exposure was ?60-70% lower with intermittent treatment.1,2
- Asthma Control Questionnaire-5 (ACQ-5): nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheeze:
- Patients with ≥ exacerbation:
- No difference in risk of exacerbation.
- Fewer asthma-controlled days with intermittent versus daily ICS.
- For children: daily ICS resulted in ~0.5cm less growth (height) at ~1 year.3
- Up to 75% of asthmatics have mild asthma.4
- Guidelines recommend daily ICS for mild persistent asthma,5 but only ~50% adhere.6
- Intermittent ICS or ICS/LABA use, compared to daily ICS, results in less overall steroid use1,2 and potential cost savings.7,8
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
